AIM Immunotech vs Kazia Therapeutics
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $27,211 for Kazia Therapeutics (3.2 times as much). AIM Immunotech grew faster (-48.2% against -98.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -49290.5%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Kazia TherapeuticsKZIA, 2025 |
|---|---|---|
| Revenue | $88,000 | $27,211 |
| Revenue growth | -48.2% | -98.2% |
| Net income | −$14.0m | −$13.4m |
| Operating margin | -13254.5% | — |
| Net margin | -15861.4% | -49290.5% |
| Return on equity | — | — |
| Free cash flow | −$11.0m | −$8.6m |
| Cash | $3.0m | $2.9m |
| Total debt | $8.0m | $260,291 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | — |
| Market value | $4.7m | $8.8m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |